*Disclosure: Not financial advice. Informational update only.*
**BioVaxys Technology Corp. ($BVAXF / CSE: BIOV)**, the clinical-stage biopharma developing **DPX™-based immunotherapies** for oncology and infectious diseases. Recent news flow highlights positive Phase 1 data and platform advancements.
# Company Snapshot
BioVaxys is a clinical-stage biopharmaceutical company focused on out-licensing immunotherapy assets from its proprietary **DPX™ platform** (lipid-in-oil delivery for sustained, targeted immune responses; compatible with peptides, mRNA, etc.). Key acquisition: IMV Inc. assets (2025), expanding ovarian cancer pipeline and patent portfolio (120+ patents, Phase 2B data). Pipeline includes **maveropepimut-S (MVP-S)** targeting survivin in multiple cancers.
* **Market Cap**: \~US$10-15M (low float; estimated from recent trading).
* **Shares Outstanding**: \~100M+ (approx.).
* **Current Price**: \~US$0.05-0.07 range (volatile; recent levels per OTC/Yahoo data; thin trading).
# Recent Activity (Dec 2025-Jan 2026)
* **Jan 8, 2026** (X): Announced promising Phase 1 results for DPX-formulated vaccines (**MVP-S** and **DPX-SurMAGE**) in non-muscle invasive bladder cancer (NMIBC). Well-tolerated; induced significant T cell responses (55% MVP-S arm); many patients recurrence-free after 2 years. Advances to potential Phase II.
* **Jan 6, 2026** (X): Highlighted Phase 1 MVP-S + letrozole in HR+/HER2- breast cancer (common subtype); strong immune responses.
* **Dec 31, 2025** (X): 2025 year-end review – DPX integration, team build; 2026 focus on out-licensing, collaborations, first royalty revenue.
* **Dec 17, 2025** (X): Positive Phase 1 MVP-S in HR+/HER2- breast cancer.
* **Dec 16, 2025** (X): Added Marianne Stanford, PhD (ex-IMV VP R&D) as advisor.
* Website emphasizes DPX superiority (no systemic release, better than LNPs for mRNA).
Check out their website for more information : [https://www.biovaxys.com/](https://www.biovaxys.com/)
Check out their twitter feed for additional information : [https://x.com/biovaxys](https://x.com/biovaxys)
Check out their most recent update : [https://investingnews.com/biovaxys-announces-phase-1-clinical-study-results-advancing-dpx-formulated-products-in-patients-with-non-muscle-invasive-bladder-cancer/](https://investingnews.com/biovaxys-announces-phase-1-clinical-study-results-advancing-dpx-formulated-products-in-patients-with-non-muscle-invasive-bladder-cancer/)